Immunotherapy （Envafolimab）

Phase 2Monoclonal antibody

Immunotherapy （Envafolimab） is one of 40 small molecule programs targeting Small Cell Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Small Cell Lung CancerActive, not recruiting

Small Cell Lung CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

598 competitors in Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Imfinzi

AstraZeneca

Phase 3

33 2

Tecentriq

Roche

Phase 3

31 3

Zepzelca

Jazz Pharmaceuticals

Phase 3

10 4

Lynparza

AstraZeneca

Phase 3

10 5

Lenvima

Eisai

Phase 3

5 6

Beyfortus

BeiGene

Phase 3

3 7

Camptosar

EEastern Cooperative Oncology Group

Phase 3

13 8

Trodelvy

Gilead

Phase 3

1 9

Cytoxan

BBaxter Healthcare Corporation

Phase 3

7 10

Etopophos

GGerman Society for Pediatric Oncology and Hematology GPOH gGmbH

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 2Recruiting

Small Cell Lung Cancer

NCT06698965

Clinical

Trials by Indication[1]

Small Cell Lung Cancer1 trial

Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin

Recruiting·SShanghai Chest Hospital·Phase 2·NCT06698965·52 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Immunotherapy （Envafolimab）. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Immunotherapy （Envafolimab） compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Immunotherapy （Envafolimab）. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Chest Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: SShanghai Chest Hospital

Immunotherapy （Envafolimab）

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News